Monograph Details
|
|
Musculoskeletal Disorders
> Bone disorders
|
|
MIACALCIN INJECTION |
| Manufacturer |
|
Novartis Pharmaceuticals Corp |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Hormone. |
| Generic Name |
|
Calcitonin-salmon 200Units/mL; SC or IM inj. |
| Also |
|
• MIACALCIN
|
| Indications |
|
Paget's disease of bone. Hypercalcemia. Postmenopausal osteoporosis. |
| Children |
|
Not recommended. |
| Adults |
|
Paget's: 100Units SC or IM daily. Hypercalcemia: initially 4Units/kg SC or IM every 12hrs, may increase after 1–2 days to 8Units/kg every 12hrs, and then after 2 more days to max 8Units/kg every 6hrs. Postmenopausal osteoporosis: 100Units SC or IM every other day. |
| Precautions |
|
For nasal spray: do periodic nasal exams; discontinue if severe ulceration occurs. For inj: monitor for hypocalcemic tetany initially and urine sediments in chronic use; serum alkaline phosphatase and hydroxyproline in Paget's. Postmenopausal osteoporosis: supplement diet with calcium (1g/day) and Vit.D; reevaluate periodically. Pregnancy (Cat.C), nursing mothers: not recommended. |
| Adverse Reactions |
|
Nasal spray: rhinitis and other nasal/respiratory symptoms, back pain, GI upset. Inj: GI upset, local inflammation, flushing, rash, antibody formation. |
| How Supplied |
Nasal spray (3.7mL)—1 (30 doses)
Inj (2mL) vial—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
